GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultimovacs ASA (STU:7UM) » Definitions » Debt-to-Revenue

Ultimovacs ASA (STU:7UM) Debt-to-Revenue : N/A (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Ultimovacs ASA Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Ultimovacs ASA's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.17 Mil. Ultimovacs ASA's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.14 Mil. Ultimovacs ASA's annualized Revenue for the quarter that ended in Mar. 2024 was €0.00 Mil.


Ultimovacs ASA Debt-to-Revenue Historical Data

The historical data trend for Ultimovacs ASA's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultimovacs ASA Debt-to-Revenue Chart

Ultimovacs ASA Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only N/A N/A N/A N/A N/A

Ultimovacs ASA Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Ultimovacs ASA's Debt-to-Revenue

For the Biotechnology subindustry, Ultimovacs ASA's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultimovacs ASA's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultimovacs ASA's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ultimovacs ASA's Debt-to-Revenue falls into.



Ultimovacs ASA Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Ultimovacs ASA's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.159 + 0.164) / N/A
=N/A

Ultimovacs ASA's annualized Debt-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.167 + 0.143) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2024) Revenue data.


Ultimovacs ASA Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ultimovacs ASA's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultimovacs ASA (STU:7UM) Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, 0379
Ultimovacs ASA is a pharmaceutical company involved in developing novel immunotherapies against cancer. Its product candidate is UV1, a peptide-based vaccine inducing T cell responses against the universal cancer antigen telomerase. The company and its proprietary technology are based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital.

Ultimovacs ASA (STU:7UM) Headlines

No Headlines